Donation after Circulatory Death Determination and Ten-Year Outcomes in Pediatric Heart Transplantation
This report was marred with ethical controversy. It was argued that reanimation of the donor heart invalidates the donor circulatory death determination, since circulatory death in the United States is defined by irreversible cardiac arrest. The resulting legal ambiguity stifled further DCD heart transplantation activity in America.2 However, the introduction of ex-situ heart perfusion and donor normothermic regional perfusion for functional assessment as well as further development of the relevant legal and ethical frameworks allowed pioneers in Australia and the United Kingdom to resume transplanting adult DCD hearts. (S...
Source: The Journal of Heart and Lung Transplantation - February 20, 2020 Category: Transplant Surgery Authors: Taufiek Konrad Rajab, James Jaggers, David N. Campbell Tags: Research Correspondence Source Type: research

Lung Transplantation for Cystic Fibrosis
This study reports on the largest single-center experience of lung transplantation for adult and pediatric CF patients. It also highlights the evolution of practice and outcomes over time. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 20, 2020 Category: Transplant Surgery Authors: Jonathan C Yeung, Tiago N Machuca, Cecilia Chaparro, Marcelo Cypel, Anne L Stephenson, Melinda Solomon, Tomohito Saito, Matthew Binnie, Chung-Wai Chow, Hartmut Grasemann, Andrew F Pierre, Kazuhiro Yasufuku, Marc de Perrot, Laura L Donahoe, Jussi Tikkanen, Tags: Original Clinical Science Source Type: research

Editorial Board
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 13, 2020 Category: Transplant Surgery Source Type: research

Information for Authors
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 13, 2020 Category: Transplant Surgery Source Type: research

Table of Contents
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 13, 2020 Category: Transplant Surgery Source Type: research

Precise treatment of acute antibody-mediated cardiac allograft rejection in rat using C4d targeted microbubbles loaded with nitric oxide
Over the past four decades, cardiac transplantation has achieved considerable success in patients with end-stage heart disease; however, the incidence of antibody-mediated rejection (AMR) remains high and is considered to be an important cause of life-threatening cardiac allograft dysfunction.1-3 (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 13, 2020 Category: Transplant Surgery Authors: Tao Liao, Qiaojia Li, Yannan Zhang, Zhe Yang, Zhengyu Huang, Fei Han, Xiaolong Chen, Tinghui Yin, Jie Ren, Qiquan Sun Tags: Original Pre-Clinical Science Source Type: research

First in human lung transplantation: adenosine a2a receptor agonist (regadenoson)
Background: Currently, no clinically available treatment exists for ischemia-reperfusion injury (IRI) following lung transplantation. Pre-clinical animal models have shown adenosine 2A receptor (A2AR) agonists are effective treatment options for reducing IRI. The purpose of this first in human study was to conduct a Phase I clinical trial to evaluate the safety of continuous infusion of an A2AR agonist in lung transplant recipients.Methods: An adaptive, 2-stage continual reassessment trial was designed to evaluate the safety of regadenoson (A2AR agonist) in the setting of lung transplantation. (Source: The Journal of Heart...
Source: The Journal of Heart and Lung Transplantation - February 13, 2020 Category: Transplant Surgery Authors: Christine L. Lau, Jared P. Beller, Joshua A. Boys, Yunge Zhao, Jennifer Phillips, Michael Cosner, Mark R. Conaway, Gina Petroni, Eric J. Charles, J. Hunter Mehaffey, Hannah C. Mannem, Irving L. Kron, Alexander S. Krupnick, Joel Linden Tags: Original Clinical Science Source Type: research

Gut microbiota, endotoxemia, inflammation and oxidative stress in heart failure, lvad and trasplant patients
Gut microbial imbalance may contribute to endotoxemia, inflammation and oxidative stress in heart failure (HF). Changes occurring in the intestinal microbiota and inflammatory/oxidative milieu during HF progression and following left ventricular assist device (LVAD) or heart transplantation (HT) are unknown. We aimed to investigate variation in gut microbiota and circulating biomarkers of endotoxemia, inflammation and oxidative stress in patients with HF (New York Heart Association (NYHA) class I-IV), LVAD and HT. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 13, 2020 Category: Transplant Surgery Authors: Melana Yuzefpolskaya, Bruno Bohn, Mojdeh Nasiri, Amelia M. Zuver, Drew D Onat, Eugene A. Royzman, Joseph Nwokocha, Melissa Mabasa, Alberto Pinsino, Danielle Brunjes, Antonia Gaudig, Autumn Clemons, Pauline Trinh, Stephania Stump, Marla J. Giddins, Veli K. Tags: Original Clinical Science Source Type: research

Pregnancy Outcomes in Heart Transplant Recipients
We describe maternal and fetal outcomes of pregnancy in the Transplant Pregnancy Registry International (TPR). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 13, 2020 Category: Transplant Surgery Authors: LR Punnoose, LA Coscia, DP Armenti, S Constantinescu, MJ Moritz Tags: Original Clinical Science Source Type: research

Rhabdomyolysis with the combined use of Danazol and Rosuvastatin in Left Ventricular Assist Devices
We present a case of severe rhabdomyolysis with concomitant administration of rosuvastatin and danazol in a patient with Heart Mate II-LVAD and refractory GIB. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 13, 2020 Category: Transplant Surgery Authors: Shivank Madan, Mandeep R. Mehra Tags: Case Anecdotes, Comments and Opinions Source Type: research

Early experience with the heartmate 3 continuous-flow ventricular assist device in pediatric and congenital heart disease patients – a multi-center registry analysis
The HeartMate 3 ventricular assist device (VAD) is a newer centrifugal continuous-flow VAD used for bridge-to-transplant and destination therapy in adults. However, there is limited experience regarding its use in children and adults with complex congenital heart disease (CHD). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 13, 2020 Category: Transplant Surgery Authors: Matthew J. O'Connor, Angela Lorts, Ryan R. Davies, Francis Fynn-Thompson, Anna Joong, Katsuhide Maeda, Christopher E. Mascio, Patrick I. McConnell, Michael C. Mong é, Deipanjan Nandi, David M. Peng, David N. Rosenthal, Ming-Sing Si, David L. Sutcliffe, C Source Type: research

Outcomes according to the International Society for Heart and Lung Tansplantation angiographic grading scale
We read with great interest the article by Van Keer et al1 assessing the long-term outcomes of cardiac allograft vasculopathy (CAV).1 We commend the authors on their large well-characterized dataset over a 25-year period and for contributing knowledge on an important disease we do not understand fully yet. This is one of the largest analyses and external validation of the International Society for Heart and Lung Transplantation (ISHLT) CAV classification system.2 We believe a few points merit further consideration. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 1, 2020 Category: Transplant Surgery Authors: Caroline McGuinty, Yasbanoo Moayedi, Sharon Chih Tags: CASE ANECDOTES, COMMENTS, AND OPINIONS Source Type: research

Letter to the Editor “Long-term outcome of cardiac allograft vasculopathy: Importance of the International Society for Heart and Lung Transplantation angiographic grading scale”
We read with great interest the article by Van Keer et al. assessing the long term outcomes of cardiac allograft vasculopathy (CAV).1 We commend the authors on their large well-characterized dataset over a 25-year period, and for contributing knowledge on an important disease we do not yet fully understand. Importantly, this is one of the largest analysis and external validation of the ISHLT CAV classification system.2 We believe a few points merit further consideration. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 1, 2020 Category: Transplant Surgery Authors: Caroline McGuinty, Yasbanoo Moayedi, Sharon Chih Tags: Case Anecdotes, Comments and Opinions Source Type: research

Awareness of bias in lung transplant registry analyses
The ideal lung transplantation procedure for patients with end-stage lung disease complicated by secondary pulmonary hypertension is currently unknown. Nasir and colleagues deserve credit for their study attempting to shed light on this controversial topic.1 They performed a contemporary, retrospective registry analysis, selecting adult recipients with obstructive or restrictive etiologies that underwent isolated lung transplantation between May 2005 and June 2015, with 12,393 recipients meeting inclusion criteria. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - February 1, 2020 Category: Transplant Surgery Authors: Neel K Ranganath, Deane E Smith, Zachary N Kon Tags: Case Anecdotes, Comments and Opinions Source Type: research

True, maybe true, perhaps unrelated – granulocyte colony-stimulating factor and increased risk of rejection in heart transplant recipients
In their 2018 published manuscript in JHLT, Nguyen et al. report an “increase in short-term risk of rejection in heart transplant patients receiving granulocyte colony-stimulating factor.”1 The authors did not detail concurrent immunosuppression reduction performed in the setting of neutropenia, a potential confounder for their result2 and commonly performed in the pediatric setting.3 Because we routinely use the granulocyte colony-stimulating factor filgrastim in our neutropenic pediatric heart transplant recipients, we reviewed whether filgrastim use was associated with rejection in our cohort. (Source: The J...
Source: The Journal of Heart and Lung Transplantation - February 1, 2020 Category: Transplant Surgery Authors: Geoffrey Hunt, Paula Gay, Waldemar F. Carlo Tags: Case Anecdotes, Comments and Opinions Source Type: research

Predicted heart mass –based size matching among recipients with moderate pulmonary hypertension: Outcomes and sex effect
There is a lack of evidence to guide appropriate donor sizing in recipients with moderate pulmonary hypertension (pHTN) awaiting heart transplantation (HTx). It is common practice to oversize donor hearts for such recipients to prevent post-operative right ventricular failure. Therefore, our objective was to determine if oversizing in pre-transplant moderate pHTN provides a survival advantage. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 31, 2020 Category: Transplant Surgery Authors: Mahek Shah, Omar Saeed, Jooyoung Shin, Sandhya Murthy, Daniel B. Sims, Sasha Vukelic, Daniel Goldstein, Stephen J. Forest, Ulrich P. Jorde, Snehal R. Patel Tags: ORIGINAL CLINICAL SCIENCE Source Type: research

Predicted heart mass based size matching among recipients with moderate pulmonary hypertension: outcomes and gender effect
There is a lack of evidence to guide appropriate donor sizing in recipients with moderate pulmonary hypertension (mod-pHTN) awaiting heart transplantation (HTx). It is common practice to oversize hearts for such recipients to prevent post-operative right ventricular failure. Therefore, our objective was to determine if oversizing in pre-transplant mod-pHTN provides a survival advantage. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 31, 2020 Category: Transplant Surgery Authors: Mahek Shah, Omar Saeed, Jooyoung Shin, Sandhya Murthy, Daniel B Sims, Sasha Vukelic, Daniel Goldstein, Stephen J Forest, Ulrich P Jorde, Snehal R Patel Tags: Original Clinical Science Source Type: research

ISHLT Consensus Statement on Donor Organ Acceptability and Management in Pediatric Heart Transplantation
The number of potential pediatric heart transplant recipients continues to exceed the number of donors and consequently the waitlist mortality remains significant. Despite this, around 40% of all donated organs are not used and are discarded. This document (62 authors from 53 institutions in 17 countries) evaluates factors responsible for discarding donor hearts and makes recommendations regarding donor heart acceptance. The aim of this statement is to ensure that no usable donor heart is discarded, waitlist mortality is reduced, and post-transplant survival is not adversely impacted. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 31, 2020 Category: Transplant Surgery Authors: Richard Kirk, Anne I Dipchand, Ryan R Davies, Oliver Miera, Gretchen Chapman, Jennifer Conway, Susan Denfield, Jeffrey G Gossett, Jonathan Johnson, Michael McCulloch, Martin Schweiger, Daniel Zimpfer, L ászló Ablonczy, Iki Adachi, Dimpna Albert, Peta Al Source Type: research

Commentary in reply to Cogswell et al.: An early investigation of outcomes with the new 2018 donor heart allocation system in the United States
It has now been just over 1 year since the implementation of significant changes to the adult heart allocation system. These changes included broader access to hearts for candidates with the highest waitlist mortality as well as a more granular stratification of candidate urgency based on historical waitlist mortality rates. Initial monitoring from the Organ Procurement and Transplant Network (OPTN) Thoracic Committee (the Committee) focused on the composition of the waitlist and characteristics of the cohort of transplanted patients. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 29, 2020 Category: Transplant Surgery Authors: Ryan R. Davies, Rebecca R. Goff, Erika D. Lease, Richard C. Daly, Shelley Hall Tags: CASE ANECDOTES, COMMENTS, AND OPINIONS Source Type: research

AAV-mediated TIMP-1 overexpression in aortic tissue reduces the severity of allograft vasculopathy in mice
Allograft vasculopathy (AV) is the main limiting factor for long-term graft survival. Increased activity of matrix metalloproteinases (MMPs) contributes to neointima formation in AV and represents a potential therapeutic target. Adeno associated viral (AAV) gene therapy comprises a potentially benign vector model for long-term expression of MMP antagonists. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 29, 2020 Category: Transplant Surgery Authors: Anca Remes, Maximilian Franz, Marcin Zaradzki, Christopher Borowski, Norbert Frey, Matthias Karck, Klaus Kallenbach, Oliver J. M üller, Andreas H. Wagner, Rawa Arif Source Type: research

Commentary in Reply to Cogswell et al: An early investigation of outcomes with the new 2018 donor heart allocation system in the United States
It has now been just over one year since the implementation of significant changes to the adult heart allocation system. These changes included broader access to hearts for candidates with the highest waitlist mortality, as well as a more granular stratification of candidate urgency based on historical waitlist mortality rates. Initial monitoring from the OPTN Thoracic Committee (the Committee) focused on the composition of the waitlist and characteristics of the cohort of transplanted patients. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 29, 2020 Category: Transplant Surgery Authors: Ryan R. Davies, Rebecca R. Goff, Erika D. Lease, Richard C. Daly, Shelley Hall Tags: Case Anecdotes, Comments and Opinions Source Type: research

Felodipine and Renal Function in Lung Transplantation: A Randomized Placebo-controlled Trial
Calcium channel blockers may ameliorate the decline in renal function caused by calcineurin inhibitors in lung transplant (LTX) recipients. We hypothesized that preoperative and 12-week postoperative treatment with the calcium channel blocker, felodipine, would reduce the decline in glomerular filtration rate (GFR). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 29, 2020 Category: Transplant Surgery Authors: M Hornum, M Iversen, P Oturai, MJ Andersen, M Zemtsovski, P Bredahl, N.H Bjarnason, K.B Christensen, J. Carlsen, CH M øller, B Feldt-Rasmussen, M Perch Tags: Original Clinical Science Source Type: research

Is it too early to investigate survival outcomes of the new US heart allocation system?
We read with interest the recent article by Cogswell et al.1 on the new heart allocation system, which concluded that post-transplant survival had significantly decreased after implementation. We have concerns about the validity of this analysis. Specifically, it appears that the authors have overlooked the important non-informative censoring assumption of the Kaplan-Meier estimator.2 This is more serious than the admitted limitation of wide confidence intervals around the estimates secondary to small sample size. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 29, 2020 Category: Transplant Surgery Authors: William F. Parker, Matthew M. Churpek, Allen S. Anderson Tags: Case Anecdotes, Comments and Opinions Source Type: research

Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy
Long-term survival following heart transplantation (HTx) is compromised by cardiac allograft vasculopathy (CAV) characterized by coronary macro and microvascular disease. The pathogenesis of CAV is unclear and may involve coronary thrombosis. We investigated whether HTx patients with CAV had higher platelet aggregation and turnover than HTx patients without CAV and healthy controls. Furthermore, we investigated the antiplatelet effect of low-dose aspirin in HTx patients. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 29, 2020 Category: Transplant Surgery Authors: Kamilla Pernille Bjerre, Tor Skibsted Clemmensen, Katrine Berg, Steen Hvitfeldt Poulsen, Anne-Mette Hvas, Erik Lerkevang Grove, Brian Bridal L øgstrup, Lars Jakobsen, Troels Thim, Steen Dalby Kristensen, Hans Eiskjær Source Type: research

Understanding Risk Factors and Predictors for Stroke Subtypes in the ENDURANCE Trials
We report a comprehensive analysis of stroke subtypes in the ENDURANCE (DT) and ENDURANCE Supplemental (DT2) trials. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 28, 2020 Category: Transplant Surgery Authors: Sung-Min Cho, Randall C. Starling, Jeffrey Teuteberg, Joseph Rogers, Francis Pagani, Palak Shah, Ken Uchino, Nicholas Hiivala Tags: Original Clinical Science Source Type: research

Endothelin-1 and Conflicting Risk Association: A New Lens A Response to Leary et al, “Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study.”
I read with interest the original science study by Leary et al entitled “Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study.1” The authors are to be congratulated for their thoughtful work pursuing the association of endothelin-1 (ET1) with cardiovascular risk in a population free from clinical cardiovascular disease at enrollment. Furt her, their counter-intuitive findings that higher ET1 were associated with higher ejection fraction and reduced risk for heart failure or cardiovascular death are thought-provoking. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 28, 2020 Category: Transplant Surgery Authors: Brian A. Houston Tags: Case Anecdotes, Comments and Opinions Source Type: research

This is Your Brain on LVAD
The utilization and duration of left ventricular assist device (LVAD) support has increased steadily over the last decade and recent changes in the UNOS heart allocation system, implemented in October 2018, portend a further increase in the duration of mechanical circulatory support for many patients (1). Though four-year survival rates have improved to 60% following LVAD implantation, the leading cause of death in these patients is neurological injury, specifically ischemic and hemorrhagic stroke (spontaneous subarachnoid hemorrhage or intraparenchymal hemorrhage [IPH]) (2). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 25, 2020 Category: Transplant Surgery Authors: Jennifer A. Frontera Tags: Editorial Source Type: research

Impact of Race on Survival in Pulmonary Arterial Hypertension: Results from the REVEAL Registry
Prior research has suggested that the prevalence and outcomes of pulmonary arterial hypertension (PAH) may vary by race or ethnicity. However, these studies have been limited by small sample size or methodological techniques relying on epidemiologic data. The purpose of this study is to evaluate the relationship between race/ethnicity and survival in a large U.S.-based prospective multicenter registry. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 24, 2020 Category: Transplant Surgery Authors: Sarah Medrek, Sandeep Sahay, Carol Zhao, Mona Selej, Adaani Frost Tags: Original Clinical Science Source Type: research

American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support
Mechanical  circulatory support (MCS) evolved from an engineering dream to clinical reality during the 1980s when increasing numbers of patients were dying on heart transplant wait lists. Following the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure Trial,1 the US Food and Drug Administration (FDA) approved a pulsatile implantable left ventricular assist device (LVAD) for long-term implantation in 2002. When the FDA approved the first US continuous flow (CF) LVAD in 2008, the landscape had changed dramatically. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 23, 2020 Category: Transplant Surgery Authors: Editors, James K. Kirklin, Francis D. Pagani, Daniel J. Goldstein, Ranjit John, Joseph G. Rogers, Contributing Authors, Pavan Atluri, Francisco A. Arabia, Anson Cheung, William Holman, Charles Hoopes, Valuvan Jeevanandam, Ranjit John, Ulrich P. Jorde, Car Tags: Adult: Mechanical Circulartory Support: AATS/ISHLT Guidelines on Selected Topics in Mechanical Circulatory Support Source Type: research

Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study
Approaches to risk assessment in pulmonary arterial hypertension (PAH) include the noninvasive French risk assessment approach (number of low-risk criteria based on the European Society of Cardiology and European Respiratory Society guidelines) and Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) 2.0 risk calculator. The prognostic and predictive value of these methods for morbidity/mortality was evaluated in the predominantly prevalent population of GRIPHON, the largest randomized controlled trial in PAH. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Olivier Sitbon, Kelly M. Chin, Richard N. Channick, Raymond L. Benza, Lilla Di Scala, Sean Gaine, Hossein-Ardeschir Ghofrani, Irene M. Lang, Vallerie V. McLaughlin, Ralph Preiss, Lewis J. Rubin, G érald Simonneau, Victor F. Tapson, Nazzareno Galiè, Mari Tags: ORIGINAL CLINICAL SCIENCE Source Type: research

Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection
In this study, we determined whether symptomatic respiratory viral infections after lung transplantation induce circulating exosomes that contain lung-associated self-antigens and assessed whether these exosomes activate immune responses to self-antigens. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Muthukumar Gunasekaran, Sandhya Bansal, Ranjithkumar Ravichandran, Monal Sharma, Sudhir Perincheri, Francisco Rodriguez, Ramsey Hachem, Cynthia E. Fisher, Ajit P. Limaye, Ashraf Omar, Michael A. Smith, Ross M. Bremner, Thalachallour Mohanakumar Tags: ORIGINAL PRE-CLINICAL SCIENCE Source Type: research

Short- and long-term adverse events in patients on temporary circulatory support before durable ventricular assist device: An IMACS registry analysis
Patients with cardiogenic shock (CS) needing temporary circulatory support (TCS) have poor survival rates after implantation of durable ventricular assist device (dVAD). We aimed to characterize post-dVAD adverse event burden and survival rates in patients requiring pre-operative TCS. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Van-Khue Ton, Rongbing Xie, Jaime A. Hernandez-Montfort, Bart Meyns, Takeshi Nakatani, Masanobu Yanase, Steve Shaw, Stephen Pettit, Ivan Netuka, James Kirklin, Daniel J. Goldstein, Jennifer Cowger Tags: Original Clinical Science Source Type: research

Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial
The objective of this study is to evaluate the efficacy and safety of ambrisentan in PoPH. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Ioana R. Preston, Charles D. Burger, Sonja Bartolome, Zeenat Safdar, Michael Krowka, Namita Sood, Hubert J. Ford, Wejdan F. Battarjee, Murali M. Chakinala, Mardi Gomberg-Maitland, Nicholas S. Hill Tags: ORIGINAL CLINICAL SCIENCE Source Type: research

Association between recipient blood type and heart transplantation outcomes in the united states
In heart transplantation (HT), while blood type O organs can go to any blood type, non-O organs may not be allocated to adult O recipients. Therefore, O candidates wait longer than non-O, and frequently require bridging with left ventricular assist devices (LVADs). The effects of this discrepancy are rarely investigated in a large registry. The purpose of the present study was to assess the association between candidates ’ blood type and their outcomes after HT listing. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Masahiko Ando, Koji Takeda, Paul A Kurlansky, Arthur R Garan, Veli K Topkara, Melana Yuzefpolskaya, Paolo C Colombo, Maryjane Farr, Yoshifumi Naka, Hiroo Takayama Tags: Original Clinical Science Source Type: research

Use of Direct Oral Anticoagulants after Heart Transplantation
In this study, we assessed the efficacy and safety of DOACs compared to warfarin after HTx. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Erik J. Henricksen, Maxime Tremblay-Gravel, Yasbanoo Moayedi, Wenjia Yang, Roy Lee, Heather J. Ross, William Hiesinger, Jeffrey J. Teuteberg, Kiran K. Khush Tags: Research Correspondence Source Type: research

Quantiferon-CMV Guided Virostatic Prophylaxis After Heart Transplantation
Cytomegalovirus (CMV) infection is the most prevalent viral infection in heart transplant recipients. Current strategies for the prevention of CMV infection after heart transplantation include either universal prophylaxis (ranging from 100 to 200 days) or preemptive therapy1,2. Since the international consensus on CMV prophylaxis and treatment2 lacks definite recommendations on optimal CMV infection prevention and the duration of prophylaxis, these are subject to significant intercenter variability. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Gregor Poglajen, Gregor Zemlji č, Sabina Frljak, Andraž Cerar, Vesna Andročec, Tamara Božič, Mojca Bitenc, Renata Okrajšek, Miran Šebeštjen, Bojan Vrtovec Tags: Research Correspondence - clinical Source Type: research

Ambrisentan in portopulmonary hypertension: A multicenter, open label trial
Ambrisentan is effective in Group 1 pulmonary arterial hypertension (PAH). Although portopulmonary hypertension (PoPH) is a subset of Group 1 PAH, few clinical trials testing PAH therapies enrolled PoPH patients. We aimed to evaluate the efficacy and safety of ambrisentan in PoPH. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Ioana R. Preston, Charles D. Burger, Sonja Bartolome, Zeenat Safdar, Michael Krowka, Namita Sood, Hubert J. Ford, Wejdan F. Battarjee, Murali M. Chakinala, Mardi Gomberg-Maitland, Nicholas S. Hill Tags: Original Clinical Science Source Type: research

Respiratory viral infection in lung-transplant induces exosomes that trigger chronic-rejection
In this study, we determined whether symptomatic respiratory viral infections in post-lung transplantation induce circulating exosomes that contain lung-associated self-antigens, and to assess whether these exosomes activate immune responses to self-antigens. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Muthukumar Gunasekaran, Ranjithkumar Ravichandran, Sandhya Bansal, Monal Sharma, Sudhir Perincheri, Francisco Rodriguez, Ramsey Hachem, Cynthia E. Fisher, Ajit P. Limaye, Ashraf Omar, Michael A. Smith, Ross M. Bremner, T Mohanakumar Tags: Original Pre-Clinical Science Source Type: research

Variability in Donor Organ Offer Acceptance and Lung Transplantation Survival
Lung transplantation (LTx) offers a survival benefit for patients with end-stage lung disease. When suitable donors are identified, centers must accept or decline the offer for a matched candidate on their waitlist. The degree to which variability in per-center offer acceptance practices impacts candidate survival is not established. The purpose of this study was to determine the degree of variability in per-center rates of LTX offer acceptance, and to ascertain the associated contribution to observed differences in per-center waitlist mortality. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: MS Mulvihill, HJ Lee, J Weber, AY Choi, ML Cox, BA Yerokun, MA Bishawi, J Klapper, M Kuchibhatla, MG Hartwig Tags: Original Clinical Science Source Type: research

Short and Long-Term Adverse Events in Patients on Temporary Circulatory Support before DURABLE VENTRICULAR ASSIST DEVICE: An IMACS Registry Analysis
Patients with cardiogenic shock (CS) needing temporary circulatory support (TCS) have poor survival after durable ventricular assist device (dVAD). We aimed to characterize post-dVAD adverse event burden and survival in those requiring pre-operative TCS. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Van-Khue Ton, Rongbing Xie, Jaime A. Hernandez-Montfort, Bart Meyns, Takeshi Nakatani, Masanobu Yanase, Steve Shaw, Stephen Pettit, Ivan Netuka, James Kirklin, Daniel J. Goldstein, Jennifer Cowger Source Type: research

Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis
Despite advances in drug development, life expectancy in idiapathic pulmonary arterial hypertension (IPAH) remains unacceptable. Contemporary IPAH characterization is based on criteria that may not adequately capture disease heterogeneity and may be proposed as a possible explanation for why patient's outcome is still unfavorable. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Roberto Badagliacca, Franz Rischard, Silvia Papa, Saad Kubba, Rebecca Vanderpool, Jason X.-J. Yuan, Joe G.N. Garcia, Sophia Airhart, Roberto Poscia, Beatrice Pezzuto, Giovanna Manzi, Cristiano Miotti, Federico Luongo, Gianmarco Scoccia, Susanna Sciomer, R Tags: Original Clinical Science Source Type: research

Risk assessment in pulmonary arterial hypertension (pah): insights from the griphon study
Approaches to risk assessment in pulmonary arterial hypertension (PAH) include the non-invasive French risk assessment approach (number of low-risk criteria based on the ESC/ERS guidelines) and REVEAL 2.0 risk calculator. The prognostic and predictive value of these methods for morbidity/mortality was evaluated in the predominantly prevalent population of GRIPHON, the largest randomized controlled trial in PAH. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 21, 2020 Category: Transplant Surgery Authors: Olivier Sitbon, Kelly M. Chin, Richard N. Channick, Raymond L. Benza, Lilla Di Scala, Sean Gaine, Hossein-Ardeschir Ghofrani, Irene M. Lang, Vallerie V. McLaughlin, Ralph Preiss, Lewis J. Rubin, G érald Simonneau, Victor F. Tapson, Nazzareno Galiè, Mari Tags: Original Clinical Science Source Type: research

Editorial Board
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 18, 2020 Category: Transplant Surgery Source Type: research

Information for Readers
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 18, 2020 Category: Transplant Surgery Source Type: research

Table of Contents
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - January 18, 2020 Category: Transplant Surgery Source Type: research

Erratum
Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D Jr, Hsich E, Meiser B, Potena L, Robinson A, Rossano JW, Sadavarte A, Singh TP, Zuckermann A, Stehlik J; International Society for Heart and Lung Transplantation.   The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report — 2019; focus theme: Donor and recipient size match.  J Heart Lung Transplant 2019;38(10):1056–1066. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - December 31, 2019 Category: Transplant Surgery Source Type: research

Editorial Board
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - December 31, 2019 Category: Transplant Surgery Source Type: research

Information for Readers
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - December 31, 2019 Category: Transplant Surgery Source Type: research

Table of Contents
(Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - December 31, 2019 Category: Transplant Surgery Source Type: research

Circulating NEDD9 is Increased in Pulmonary Arterial Hypertension: A Multicenter, Retrospective Analysis
Pulmonary arterial hypertension (PAH) is a highly morbid disease characterized by elevated pulmonary vascular resistance (PVR) and pathogenic right ventricular (RV) remodeling. Endothelial expression of the pro-metastatic protein NEDD9 is increased in fibrotic PAH arterioles, and NEDD9 inhibition decreases PVR in experimental PAH. We hypothesized that circulating NEDD9 is increased in PAH and informs the clinical profile of patients. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - December 31, 2019 Category: Transplant Surgery Authors: Andriy O. Samokhin, Steven Hsu, Paul B. Yu, Aaron B. Waxman, George A. Alba, Bradley M. Wertheim, C. Danielle Hopkins, Frederick Bowman, Richard N. Channick, Ivana Nikolic, Mariana Faria-Urbina, Paul M. Hassoun, Jane A. Leopold, Ryan J. Tedford, Corey E. Source Type: research